December 10, 2020 10:32 AM ESTUpdated January 11, 09:49 PM
R&D

An­gling for a spot among the gi­ants, TG Ther­a­peu­tics touts PhI­II MS da­ta for CD20 drug

Amber Tong

While the phar­ma gi­ants duke it out in mul­ti­ple scle­ro­sis, a biotech is tak­ing a crack at the shak­ing up the mar­ket. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times